News|Videos|December 8, 2020

Further Testing Rivipansel and Its Implications Through the RESET Clinical Trial

Helen Thackray, MD, dives deeper into how the researchers tested rivipansel on the study participants and the implications compared to previous trials.

Pharmacy Times interviewed Helen Thackray, MD, on her presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into rivipansel for acute vaso-occlusive crisis in sickle cell disease and the RESET clinical trial. In this video, Thackray dives deeper into how the researchers tested rivipansel on the study participants and the implications compared to previous trials.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related to this article

October 5th, 2026

Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?

In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.

September 30th, 2026

September 2026 in Hematology: 5 Updates That Pharmacists Should Know

September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.

September 28th, 2026

CRS With Linvoseltamab Peaks 6 to 8 Hours After First Step-Up Dose

A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.

September 26th, 2026

Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma

An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.

Glp-1 injection pen and tape measure symbolizing weight loss and obesity treatment

October 6th, 2026

Petrelintide Yields Up to 10.7% Weight Loss With Mild GI Effects

In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.

October 6th, 2026

Semaglutide Normalized Liver Fat in Most Adults With Obesity

Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.

Streptococcus pneumonia bacteria cells. 3D render microscopic background with copy space - Image credit: Jezper | stock.adobe.com

October 5th, 2026

Expert Q&A: Severe Pneumococcal Infection May Signal Hidden Blood Cancer or Immunodeficiency

Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.

Orforglipron, non-peptide GLP-1 capsules for weight loss

October 5th, 2026

Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4

In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.

Further Testing Rivipansel and Its Implications Through the RESET Clinical Trial

Related to this article

Trending on Pharmacy Times

Semaglutide Normalized Liver Fat in Most Adults With Obesity

Reframing Statins and Brain Health Around Stroke Prevention

Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge

mRNA Reenters the Mainstream

Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?